Nothing Special   »   [go: up one dir, main page]

BR112019001233A2 - formulação farmacêutica e uso da mesma - Google Patents

formulação farmacêutica e uso da mesma

Info

Publication number
BR112019001233A2
BR112019001233A2 BR112019001233A BR112019001233A BR112019001233A2 BR 112019001233 A2 BR112019001233 A2 BR 112019001233A2 BR 112019001233 A BR112019001233 A BR 112019001233A BR 112019001233 A BR112019001233 A BR 112019001233A BR 112019001233 A2 BR112019001233 A2 BR 112019001233A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
antibodies
relates
present
pharmaceutical formulations
Prior art date
Application number
BR112019001233A
Other languages
English (en)
Other versions
BR112019001233B1 (pt
Inventor
Li Junfeng
Cao Wei
Liu Xiaolin
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of BR112019001233A2 publication Critical patent/BR112019001233A2/pt
Publication of BR112019001233B1 publication Critical patent/BR112019001233B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a presente invenção refere-se a formulações farmacêuticas para anticorpos anti-pd-1.
BR112019001233-8A 2016-08-09 2017-07-17 Formulação farmacêutica e uso da mesma BR112019001233B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2016/094094 WO2018027524A1 (en) 2016-08-09 2016-08-09 Pd-1 antibody formulation
CNPCT/CN2016/094094 2016-08-09
PCT/CN2017/093141 WO2018028383A1 (en) 2016-08-09 2017-07-17 Pd-1 antibody formulation

Publications (2)

Publication Number Publication Date
BR112019001233A2 true BR112019001233A2 (pt) 2019-06-25
BR112019001233B1 BR112019001233B1 (pt) 2021-10-26

Family

ID=61161074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001233-8A BR112019001233B1 (pt) 2016-08-09 2017-07-17 Formulação farmacêutica e uso da mesma

Country Status (9)

Country Link
US (1) US11130809B2 (pt)
EP (1) EP3496753B1 (pt)
JP (1) JP6848046B2 (pt)
CN (1) CN109562173B (pt)
AU (1) AU2017310916B2 (pt)
BR (1) BR112019001233B1 (pt)
CA (1) CA3030929C (pt)
ES (1) ES2969233T3 (pt)
WO (2) WO2018027524A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016348388B2 (en) 2015-11-03 2023-11-30 Janssen Biotech, Inc. Antibodies specifically binding PD-1 and their uses
CN109498565B (zh) * 2018-12-27 2021-06-29 兴盟生物医药(苏州)有限公司 一种稳定的抗pd-1抗体制剂及其用途
JP6802598B1 (ja) 2019-07-18 2020-12-16 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 抗がん剤の効果増強剤
KR20210013760A (ko) * 2019-07-18 2021-02-05 데루타-후라이 화마 가부시키가이샤 항암제의 효과 증강제
WO2021123202A1 (en) 2019-12-20 2021-06-24 Formycon Ag Formulations of anti-pd1 antibodies
CN110787292B (zh) * 2020-01-06 2020-04-24 上海复宏汉霖生物技术股份有限公司 一种细胞程序性死亡受体1抗体制剂及其用途
TW202130367A (zh) * 2020-01-15 2021-08-16 大陸商信達生物製藥（蘇州）有限公司 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途
KR20230026446A (ko) * 2020-06-19 2023-02-24 사이노셀테크 엘티디. 재조합 항-pd-1 단일클론 항체를 위한 안정한 제형
JP2024527517A (ja) 2021-06-23 2024-07-25 フォーマイコン アーゲー 抗ｐｄ１抗体製剤
WO2024133625A1 (en) 2022-12-21 2024-06-27 Formycon Ag Formulations of anti-pd1 antibodies
WO2024171082A1 (en) 2023-02-16 2024-08-22 Sun Pharmaceutical Industries Limited Stable protein compositions of anti-pd1 antibody

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
US8993731B2 (en) * 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
PT2691112T (pt) * 2011-03-31 2018-07-10 Merck Sharp & Dohme Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3049441B1 (en) * 2013-09-27 2019-11-27 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
CN104740612A (zh) * 2013-12-31 2015-07-01 上海中信国健药业股份有限公司 一种受体抗体融合蛋白的液体制剂
WO2016011357A1 (en) 2014-07-18 2016-01-21 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
CA2955676A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
EP3194440A1 (en) * 2014-09-15 2017-07-26 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
JP6827415B2 (ja) * 2014-10-31 2021-02-10 メレオ バイオファーマ ５ インコーポレイテッド 疾患の処置のための併用療法
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies

Also Published As

Publication number Publication date
AU2017310916A1 (en) 2019-03-07
EP3496753A1 (en) 2019-06-19
WO2018027524A1 (en) 2018-02-15
ES2969233T3 (es) 2024-05-17
JP2019527712A (ja) 2019-10-03
CN109562173A (zh) 2019-04-02
CN109562173B (zh) 2022-09-02
EP3496753A4 (en) 2020-04-01
US11130809B2 (en) 2021-09-28
AU2017310916B2 (en) 2020-02-06
CA3030929A1 (en) 2018-02-15
US20210040211A1 (en) 2021-02-11
WO2018028383A1 (en) 2018-02-15
BR112019001233B1 (pt) 2021-10-26
CA3030929C (en) 2022-06-21
JP6848046B2 (ja) 2021-03-24
EP3496753B1 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
DK3386541T3 (da) Vandig farmaceutisk formulering omfattende anti-pd-1-antistof avelumab
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
BR112017020358A2 (pt) composição farmacêutica de tetraciclina para uso dermatológico
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
DK3504241T3 (da) Anti-cd3-antistofformuleringer
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112017007393A2 (pt) composições de anticorpo anti-il-7r
DK3634377T3 (da) Farmaceutisk formulering
MA46867A (fr) Formulations pharmaceutiques
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112021016198A2 (pt) Formulações de anticorpo anti-il-36r
ES2983242T3 (es) Formulación para anticuerpo y conjugado de fármaco del mismo
MA43705A (fr) Formulation pharmaceutique
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
BR112017002090A2 (pt) formulação de fator viii
CO2017011295A2 (es) Piroglutamato de vortioxetina
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/07/2017, OBSERVADAS AS CONDICOES LEGAIS.